Compare Amphastar Pharmaceuticals Inc (AMPH) vs Zeta Global Holdings Corp (ZETA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

ZETA trades at $21.49, down 1.94% on the day, with a bullish technical signal from moving averages and strong analyst support. The company demonstrates robust revenue growth, reaching $1.30B in 2025, and has consistently beaten earnings expectations in recent quarters. Recent news highlights its strategic AI partnership with Palantir and expansion of its Athena AI platform, driving positive investor sentiment despite current negative profitability metrics.

The outlook for ZETA is positive, with a consensus price target of $27.50 implying 28% upside. Key opportunities include AI-driven growth and market share gains, but risks involve persistent negative net margins and cash flow challenges. Investors should weigh the strong growth trajectory against profitability concerns before committing capital.